Oncology - May 30, 2023 - Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

Can't see this email? View it online

	Oncology
	The latest oncology news from News Medical

	Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM).

	New method can kill aggressive brain tumors Researchers at the University of Gothenburg, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma.

			Potential benefits and drawbacks of using AI tools in the field of clinical radiology Since the launch of ChatGPT in November 2022, the use of large language models (LLMs) powered by artificial intelligence (AI) has taken the world by storm.

			Addressing sexual health issues of breast cancer patients on endocrine therapy Breast cancer treatments that can save a woman's life can seriously harm her sexual health, says Dr. Kristin E. Rojas, a breast cancer surgeon at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

			Markey one of 71 NCI designated cancer centers in the U.S. When the University of Kentucky Markey Cancer Center earned a designation the National Cancer Institute (NCI) in 2013, it instantly established Markey as one of the top cancer research centers in the U.S.

	2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers The Pediatric Cancer Research Foundation, a nonproﬁt focused on transforming pediatric cancer care by accelerating research breakthroughs, today announced the 19 recipients of its 2023 research grants.

	Predicting the sensitivity of platinum-based chemotherapy for ovarian cancer patients This article talks about a prospective cohort study that indicated HRD testing could accurately predict the sensitivity of platinum-based chemotherapy for ovarian cancer patients.

	Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023 Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

	Telephone-based weight loss program can help patients with breast cancer to reduce their weight Women with obesity when they are diagnosed with early breast cancer have a higher risk of recurrence or a second cancer compared to women whose weight is in the normal range and it can be hard to lose weight after being diagnosed with breast cancer.

	AI-POD project poised to revolutionize the prediction and treatment of obesity-related CVDs Over the course of four years, experts from various fields, including radiology, computational imaging research and industry, will collaborate to develop a state-of-the-art imaging-based AI risk score, a clinical decision support system (CDSS), and a mobile app for personalized risk assessment and prediction of obesity-related CVDs and their associated complications.

	PCCT offers better cardiovascular imaging quality in infants with suspected congenital heart defects A new advanced form of CT imaging called photon-counting computed tomography (PCCT) offers better cardiovascular imaging quality at a similar radiation dose compared to dual-source CT (DSCT) in infants with suspected cardiac heart defects, according to a study published in Radiology, a journal of the Radiological Society of North America.

	Activated B cells in gastrointestinal tract contribute to the development of liver cancer Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. I

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions